References
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification, and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–7.
Vermeersch P, Vercammen M, Holvoet A, Vande Broek I, Delforge M, Bossuyt X. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders. Clin Chim Acta. 2009;410:54–8.
Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chains and with immunofixation of serum and urine. Clin Chem. 2009;55:499–504.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.
Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673–80.
te Velthuis H, Knop I, Stam P, et al. N Latex FLC – new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med. 2011;49:1323–32.
Carr-Smith HD, Jenner EL, Evans JAR, Harding SJ. Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents. Clin Chem Lab Med. 2016;54:997–1003.
Palladini G, Jaccard A, Milani P, et al. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clin Chem Lab Med. 2017;55:1734–43.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet. 2014;15:e538–48.
Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941–6
Acknowledgements
We thank Siemens and The Binding site for providing the reagents and for performing the assays. We thank Oscar Berlanga and Stephen Harding (both from the Binding Site) and Carola Wagner (from Siemens) for helpful discussions.
Author contribution
XB and MV designed the study and wrote the paper. XB, MV, MR, and DD analyzed the data. MD, KF, and BS take care of the patients with multiple myeloma and revised the manuscript. KP discussed the data and critically reviewed the study and the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
MV, KP, and XB received travel fees from The Binding Site. BS received research support from The Binding Site. The remaining authors declare no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Bossuyt, X., Delforge, M., Reynders, M. et al. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Leukemia 32, 1815–1818 (2018). https://doi.org/10.1038/s41375-018-0041-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0041-0
- Springer Nature Limited
This article is cited by
-
A Comparative Analysis of Freelite and N Latex FLC Assay for the sFLC Measurements in Suspected Patients of Monoclonal Gammopathy
Indian Journal of Hematology and Blood Transfusion (2024)
-
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
Blood Cancer Journal (2020)